Unknown primary molecular target

The term 'Unknown primary molecular target' is a placeholder designation used in pharmacology and drug development to indicate that the specific biological molecule—such as a receptor, enzyme, or ion channel—responsible for a drug's therapeutic effect has not been identified (Swinney and Anthony, 2011). This situation is common for drugs discovered through phenotypic screening, where a compound is found to produce a desired biological response in a cell or organism without prior knowledge of its binding partner (Terstappen et al., 2007). While such drugs can be clinically effective, the lack of a defined target presents significant hurdles for optimizing the drug's chemical structure and predicting potential off-target toxicities (Ziegler et al., 2013). Modern drug discovery often involves 'target deconvolution' to identify these unknown targets using techniques like chemical proteomics, mass spectrometry, or genetic profiling (Haura, 2008). Understanding the primary target is essential for transitioning from empirical observation to rational drug design and for the development of biomarkers to monitor efficacy (Kinnings et al., 2009). Consequently, many drugs currently in clinical use are being retrospectively studied to uncover their underlying molecular interactions and improve their safety profiles (Eder et al., 2014). Identifying the molecular target remains a critical milestone in the drug development process, as it enables the use of structure-based drug design to enhance potency and selectivity (Schenone et al., 2013).

Other names

Unidentified targetTarget unknownMechanism of action unknown

The mechanism of action is currently undefined as the primary molecular target has not been identified.